Helix BioPharma Corp. will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, focusing on its clinical development progress and corporate milestones. The company will highlight preparations for a Phase Ib/Randomized Phase II clinical study of L-DOS47 in combination with pembrolizumab for first-line treatment of non-small cell lung cancer (NSCLC). This presentation is significant as it demonstrates ongoing advancement in addressing hard-to-treat cancers through innovative therapeutic approaches.
The clinical study represents a critical step in developing new treatment options for NSCLC patients, potentially improving outcomes for those with limited current alternatives. L-DOS47, described as a Tumor Defense Breaker™, is designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and enhance the effectiveness of existing anti-cancer treatments. The combination approach with pembrolizumab could offer new hope for patients facing this challenging cancer type.
Additionally, Helix will discuss its planned uplisting to NASDAQ in Q1 2026, a strategic move that could provide broader market visibility and access to global capital markets. This corporate development is important as it may enable increased investment in oncology research and development, potentially accelerating the delivery of new cancer treatments to patients. The presentation will be delivered by CEO Thomas Mehrling, MD, PhD, who will also participate in one-on-one meetings with investors.
The Investor Summit event, organized by Investor Summit Group, serves as a platform for connecting emerging companies with serious investors. Investors can access the presentation through the webcast link and register for the event at the registration page. These developments in both clinical progress and corporate strategy position Helix BioPharma to potentially make significant contributions to oncology treatment while expanding its market presence and research capabilities.
